We have introduced management targets covering environmental, social and governance (ESG) topics, in alignment with our company-level priority of building trust with society. The topics covered include pricing and access to medicines, global health challenges, ethics, risk and compliance and environmental sustainability.
  • Invest USD 250 million to advance R&D for neglected tropical diseases (NTDs) and malaria (over 5 years from 2021-2025)
  • Implement a global access strategy for all new medicines launched
  • Increase patients reached with strategic innovative medicines in LMICs1 by at least 200% by 2025 (vs. 2019)
  • Increase by at least 50% the number of patients reached with global health flagship programs (malaria, leprosy, chagas, sickle cell disease) in LMICs1 by 2025 (vs. 2019)

Third-party risk management (TPRM)

  • Conduct risk assessments for all new eligible suppliers

Learn more about our approach to third-party risk management

Environmental sustainability

  • 2025: Be carbon neutral in our own operations (Scope 1 and 2)2; Include environmental criteria in all supplier contracts
  • 2030: Achieve carbon neutrality across our value chain (Scope 1, 2, 3)
  • 2040: Achieve net zero carbon emissions across our value chain (Scope 1, 2, 3)3

Learn more about our efforts to reduce our impacts on climate

  • 2025: Reduce water consumption in our operations by half4, with no water quality impacts from manufacturing effluents
  • 2030: Be water neutral in all areas of our own operations versus 2016 baseline5, while actively enhancing water quality wherever we operate

Learn more about our efforts to reduce our impacts on water

  • 2025: Eliminate polyvinyl chloride (PVC) in packaging6 and reduce the amount of waste sent for disposal by half4
  • 2030: Be plastic neutral7, with all new products meeting sustainable design principles

Learn more about our efforts to reduce our impacts on waste

Diversity and inclusion

  • Achieve gender balance in management by 2023
  • Close the gender pay gap by 2023
  • Remove bias from the system by eliminating the use of historical salary data by 2023
  • Create pay transparency for employees by 2023

Explore our Novartis in Society Integrated report (PDF 8.8 MB) to see how we performed in 2022.

Learn more about our approach to ESG topics

References:

  1. Low- and middle-income countries as defined in sustainability-linked bond prospectus
  2. Scope 1 and Scope 2 from energy
  3. In accordance with SBTi net-zero standard
  4. Vs. 2016 baseline performance
  5. All Novartis sites to reduce water consumption in all areas and be water neutral in water-stressed regions by not depleting local water reserves. Water-stressed regions are determined using WWF water risk filter
  6. Defined as secondary and tertiary packaging; primary packaging when feasible
  7. Plastic neutral defined as weight of plastic packaging entering the environment for disposal is approximately the same as weight being recovered for recycling